- Home
- MLYS vs NXP Comparison
MLYS vs NXP Comparison
Compare MLYS & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- NXP
- Stock Information
- Founded
- MLYS 2019
- NXP 1992
- Country
- MLYS United States
- NXP United States
- Employees
- MLYS N/A
- NXP N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- MLYS Health Care
- NXP Finance
- Exchange
- MLYS Nasdaq
- NXP Nasdaq
- Market Cap
- MLYS 893.0M
- NXP 730.9M
- IPO Year
- MLYS 2023
- NXP N/A
- Fundamental
- Price
- MLYS $15.14
- NXP $14.23
- Analyst Decision
- MLYS Strong Buy
- NXP
- Analyst Count
- MLYS 3
- NXP 0
- Target Price
- MLYS $33.00
- NXP N/A
- AVG Volume (30 Days)
- MLYS 679.3K
- NXP 70.0K
- Earning Date
- MLYS 05-12-2025
- NXP 01-01-0001
- Dividend Yield
- MLYS N/A
- NXP 4.04%
- EPS Growth
- MLYS N/A
- NXP N/A
- EPS
- MLYS N/A
- NXP 0.54
- Revenue
- MLYS N/A
- NXP N/A
- Revenue This Year
- MLYS N/A
- NXP N/A
- Revenue Next Year
- MLYS N/A
- NXP N/A
- P/E Ratio
- MLYS N/A
- NXP $26.81
- Revenue Growth
- MLYS N/A
- NXP N/A
- 52 Week Low
- MLYS $8.24
- NXP $12.91
- 52 Week High
- MLYS $18.38
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- MLYS 61.10
- NXP 61.57
- Support Level
- MLYS $14.03
- NXP $13.78
- Resistance Level
- MLYS $15.79
- NXP $14.33
- Average True Range (ATR)
- MLYS 0.93
- NXP 0.15
- MACD
- MLYS 0.16
- NXP 0.06
- Stochastic Oscillator
- MLYS 92.27
- NXP 86.28
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.